Global Information
회사소개 | 문의 | 위시리스트

세계의 듀셴형 근이영양증 치료제 시장

Duchenne Muscular Dystrophy Drugs

리서치사 Global Industry Analysts, Inc.
발행일 2019년 10월 상품 코드 893737
페이지 정보 영문 94 Pages
가격
US $ 4,950 ₩ 5,859,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 17,579,000 PDF by E-mail (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 듀셴형 근이영양증 치료제 시장 Duchenne Muscular Dystrophy Drugs
발행일 : 2019년 10월 페이지 정보 : 영문 94 Pages

세계의 듀셴형 근이영양증 치료제(Duchenne Muscular Dystrophy Drug) 시장에 대해 조사했으며, 시장 동향과 부문별 동향, 지역별 예측, 시장 진출기업 개요에 대해 정리했습니다.

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
    • 강력한 성장을 나타내는 듀셴형 근이영양증 치료제 시장
    • 세계 경쟁 기업의 시장 점유율
    • 세계 시장 점유율 시나리오
    • 부문별 시장 점유율
    • 돌연변이 억제
    • Exon Skipping
    • 세계 시장 동향
    • 치료 개요와 최근 발전
    • 치료에 사용되는 스테로이드
    • 유아에게 Translarna가 바람직한 결과를 나타낸다
    • Emflaza가 코르티코스테로이드보다 운동기능을 더 잘 유지함이 임상시험에서 밝혀진다
    • Golodirsen이 DMD 환자의 디스트로핀 생산을 증가시키는 것으로 나타난 임상시험
    • 미국 식품의약국(FDA)이 듀셴형 근이영양증 치료용 코르티코스테로이드 Emflaza를 승인
  • 주요 시장 진출기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 지역별 시장 분석
  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽 국가
  • 아시아태평양
  • 기타 국가

제4장 경쟁

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • NIPPON SHOKUBAI
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • TAIHO PHARMACEUTICAL

제5장 관련 조사

LSH 19.08.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Duchenne Muscular Dystrophy Drugs market worldwide is projected to grow by US$4.9 Billion, driven by a compounded growth of 40.5%. Mutation Suppression, one of the segments analyzed and sized in this study, displays the potential to grow at over 39%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.9 Billion by the year 2025, Mutation Suppression will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 45% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$141.4 Million to the region's size and clout in the next 5 to 6 years. Over US$226.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Mutation Suppression will reach a market size of US$144.6 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 38.9% over the next couple of years and add approximately US$809.3 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, Acceleron Pharma, Inc.; Akashi Therapeutics, Inc.; BioMarin Pharmaceutical, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Nippon Shokubai Co., Ltd.; Nobelpharma Co., Ltd.; Pfizer, Inc.; PTC Therapeutics, Inc.; Sarepta Therapeutics Inc.; Taiho Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth
  • Global Competitor Market Shares
  • Duchenne Muscular Dystrophy Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Global Market Dynamics
  • Treatment Overview and Recent Developments
  • Steroids used for the Treatment of DMD
  • Translarna Exhibits Positive Result in Children with DMD
  • Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
  • Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
  • Casimersen and Golodirsen Exhibits Positive Results in Sarepta's ESSENCE study
  • EXONDYS 51(r) Drug Details
  • FDA Approves Corticosteroid Emflaza for Treating DMD Patients

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Pipeline Analysis
  • Drug Price Details: Exondys51
  • Sarepta's DMD Gene Therapy Trial Update

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Duchenne Muscular Dystrophy Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025
  • TABLE 2: Duchenne Muscular Dystrophy Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017
  • TABLE 3: Duchenne Muscular Dystrophy Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Mutation Suppression (Segment) World Market by Region/Country in US$ Thousand: 2018 to 2025
  • TABLE 5: Mutation Suppression (Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 6: Mutation Suppression (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Exon Skipping (Segment) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 8: Exon Skipping (Segment) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 9: Exon Skipping (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Other Segments (Segment) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 11: Other Segments (Segment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017
  • TABLE 12: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Duchenne Muscular Dystrophy Drugs Market Share (in %) by Company: 2019 & 2025
    • TABLE 13: United States Duchenne Muscular Dystrophy Drugs Market Estimates and Projections in US$ Thousand by Segment: 2018 to 2025
    • TABLE 14: Duchenne Muscular Dystrophy Drugs Market in the United States by Segment: A Historic Review in US$ Thousand for 2009-2017
    • TABLE 15: United States Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 16: Canadian Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 17: Canadian Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 18: Duchenne Muscular Dystrophy Drugs Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • JAPAN
    • TABLE 19: Japanese Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 20: Duchenne Muscular Dystrophy Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 21: Japanese Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 22: Chinese Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 23: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in China in US$ Thousand by Segment: 2009-2017
    • TABLE 24: Chinese Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Duchenne Muscular Dystrophy Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug
    • CHMP Rejects Exondys 51 in Europe
    • TABLE 25: European Duchenne Muscular Dystrophy Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025
    • TABLE 26: Duchenne Muscular Dystrophy Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017
    • TABLE 27: European Duchenne Muscular Dystrophy Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 28: European Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 29: Duchenne Muscular Dystrophy Drugs Market in Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 30: European Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 31: Duchenne Muscular Dystrophy Drugs Market in France by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 32: French Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 33: French Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 34: Duchenne Muscular Dystrophy Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 35: German Duchenne Muscular Dystrophy Drugs Historic Market Analysis in US$ Thousand by Segment: 2009-2017
    • TABLE 36: German Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 37: Italian Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 38: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in Italy in US$ Thousand by Segment: 2009-2017
    • TABLE 39: Italian Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 40: United Kingdom Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 41: Duchenne Muscular Dystrophy Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 42: United Kingdom Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 44: Duchenne Muscular Dystrophy Drugs Market in Rest of Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 45: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 46: Duchenne Muscular Dystrophy Drugs Market in Asia-Pacific by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 47: Asia-Pacific Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 48: Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF WORLD
    • TABLE 49: Rest of World Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 50: Rest of World Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 51: Duchenne Muscular Dystrophy Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025

IV. COMPETITION

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • NIPPON SHOKUBAI
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • TAIHO PHARMACEUTICAL

V. CURATED RESEARCH

Back to Top
전화 문의
F A Q